GSMA
25.2.2020 13:02:04 CET | Business Wire | Press release
The GSMA today announced winners of the 2020 Global Mobile (GLOMO) Awards. The GLOMOs showcase those companies and individuals that are driving innovation in the rapidly evolving mobile industry.
“Our congratulations to all of the winners and nominees of the GSMA’s GLOMO Awards 2020,” said John Hoffman, CEO, GSMA Ltd. “The GLOMOs are a testament to the incredible innovation and ingenuity shaping our industry and it is truly an outstanding achievement to have been selected by our esteemed judging panels. We thank all of our entrants, judges, sponsors and partners for supporting the 2020 GLOMOs.”
The winners of the 2020 GLOMO Awards are:
Best Mobile Network Infrastructure
Vodafone, Parallel Wireless and Telecom Infra Project for Global OpenRAN Deployments
Best Mobile Technology Breakthrough (Companies > $10million Annual Global Revenue)
Ericsson for Ericsson Spectrum Sharing (ESS)
Best Mobile Technology Breakthrough (Companies < $10million Annual Global Revenue)
KaiOS for KaiOS, Enable Tomorrow
Best Network Software Breakthrough (Companies > $10million Annual Global Revenue)
Parallel Wireless for OpenRAN Controller and Network Software
Best Network Software Breakthrough (Companies < $10million Annual Global Revenue)
Cohere Technologies for Improved 4G and 5G FDD/TDD Networks
Best Mobile Authentication & Security Solution
Nuance Communications Inc. for Nuance Gatekeeper
5G Leadership Award
Huawei for Gear up with Huawei’s E2E 5G Products
5G Industry Partnership Award
China Unicom, BMW & Huawei for 5G Digital Factory Enable Automobile Manufacturing Digital Transformation
Outstanding Mobile Technology Award
Ericsson for Ericsson Spectrum Sharing (ESS)
Best Mobile Operator Service for Consumers
Vimplecom for Beeline & Liza Alert
Best Mobile service for the Connected Life
CalAmp for Here Comes The Bus
Most Innovative Mobile App
Turkcell for BiP Translate
Best Mobile Innovation for Work
China Eastern Airlines, China Unicom & Huawei for 5G Smart Travel in Airport
Best Mobile Innovation for Health and Biotech
Flare for World-Class Emergency Response Technologies
Best Mobile Innovation for Automotive
SK Telecom for Smart Fleet: Data Analytics Platform for Intelligent Mobility
Best Mobile Innovation for Payment and FinTech
Juvo for Financial Identity as a Service (FiDaaS)
Best Mobile Innovation for Smart Cities
China Mobile Group Zhejiang and Huawei for NB-IoT Smart City Fire Control
Best Mobile Innovation for Media and Entertainment
LG Uplus for U+VR 5G
Best Mobile Innovation for Building Trust in the Digital Age
Samsung Electronics for Knox Security Platform
Tech of the Future Award
Huawei for Atlas 900 AI Cluster - The Pinnacle of AI Compute for Future Inclusion
Best Smartphone
OnePlus for OnePlus 7T Pro
Disruptive Device Innovation Award
Qualcomm for Qualcomm Snapdragon X55 5G modem
Best Connected Consumer Device
Vasco Electronics for Vasco Mini2
Best Mobile Innovation for Emerging Markets
Safaricom for DigiFarm
Best Mobile Innovation supporting Emergency or Humanitarian Situations
MapSwipe for Missing Maps
Best Mobile Innovation for Accessibility & Inclusion
SK Telecom for Driving Assistance Solution for Hearing-Impaired Taxi Driver
Best Mobile Innovation for Climate Action
Huawei for Huawei PowerStar™ Solution, 3-Level AI-Based Energy Saving solution
Best Mobile Initiative for Enhancing Children’s Lives
Accenture for SAATHI – Autism Therapy at your Fingertips
Outstanding Mobile Contribution to the UN SDGs
KT for Global Epidemic Prevention Platform
Government Leadership Award
The Government of the Kingdom of Saudi Arabia
Outstanding Contribution to the Mobile Industry
Safaricom
Women4Technology – Industry Leadership Award
Elena Sinel, Founder for Teens In AI
Diversity in Tech Award
Teens In AI for Teens In AI
25 Years of Connecting People Award
Dr Mike Short - A constant champion of the role of mobile technology for the enhancement of society
YoMo STEAM Activity for Children Award
SK Telecom for Happy Coding School for Adolescents with Special Needs
For further information on GLOMO Awards winners please visit https://www.globalmobileawards.com/
- ENDS-
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators and nearly 400 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.
For more information, please visit the GSMA corporate website at www.gsma.com . Follow the GSMA on Twitter: @GSMA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200225005494/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom